Concern about side effects is one of the most common reasons men delay starting testosterone replacement therapy — sometimes for years, while their quality of life continues to decline. Online forums and health anxiety can make TRT sound dangerous. The reality is considerably more nuanced.
The side effects of properly prescribed and monitored TRT are real — they are worth knowing about and worth managing. But they are not the unpredictable, dramatic risks that some corners of the internet suggest. In well-managed clinical practice, the vast majority of TRT side effects are predictable, detectable through routine blood monitoring, and entirely manageable through dose adjustment or adjunct treatment.
At Vitalis Luxe Clinic in Hull, we believe that informed patients make better treatment decisions — and experience better outcomes. This article covers every clinically significant side effect of TRT: what causes it, how common it is, how it is monitored, and what can be done about it. We serve men across Hull, East Yorkshire, and throughout Yorkshire, and this is the honest briefing we give every patient before they start.
1: Erythrocytosis (Elevated Red Blood Cell Count / Haematocrit
Erythrocytosis — an increase in red blood cell production leading to elevated haematocrit (the proportion of blood volume occupied by red cells) — is the most clinically significant side effect of testosterone replacement therapy and the one requiring the most consistent monitoring.
Testosterone stimulates erythropoiesis (red blood cell production) by increasing erythropoietin levels. This effect can raise haematocrit to levels that increase blood viscosity — making the blood ‘thicker’ — which in turn is associated with increased risk of thromboembolic events (blood clots, stroke, deep vein thrombosis) if not managed.
How Common and How Managed
- Occurs in approximately 20–30% of men on TRT to some degree; clinically significant elevation in a smaller proportion
- More common with injectable testosterone preparations (particularly shorter-acting injectables dosed infrequently) than with gels or more frequently dosed injections
- Monitored via full blood count (haematocrit) at 3 months, 6 months, and annually thereafter
- Management: dose reduction, switching to a preparation with a flatter pharmacokinetic profile, increasing injection frequency, therapeutic venesection (blood donation) to reduce haematocrit
- Target haematocrit during TRT: below 0.54 (54%) — above this level, dose adjustment or venesection is indicated
2: Elevated Oestradiol and Related Effects
Testosterone is converted to oestradiol (oestrogen) in peripheral tissues through the enzyme aromatase. When testosterone levels rise on TRT, oestradiol levels also rise — and in some men, particularly those with higher body fat (which contains more aromatase), this conversion can become excessive.
Symptoms of Elevated Oestradiol
- Gynaecomastia — breast tissue development or tenderness (the most concerning oestradiol-related side effect for most men)
- Water retention and bloating
- Mood changes — irritability, emotional lability
- Reduced libido (paradoxically — excessive oestradiol can suppress sexual drive despite adequate testosterone)
- Nipple sensitivity or discharge
Management
- Oestradiol measured at baseline and during monitoring — a well-managed TRT protocol routinely includes E2 assessment
- Dose adjustment — reducing testosterone dose often reduces oestradiol conversion
- Aromatase inhibitors (AIs) such as anastrozole — used selectively where oestradiol is consistently elevated and causing symptoms; not used routinely as oestradiol has important functions in men including bone health, libido, and cardiovascular protection
- Body composition — reducing visceral fat meaningfully reduces aromatase activity and is a non-pharmacological approach to managing oestradiol
3: Testicular Atrophy and Fertility Suppression
As described in our article on TRT and fertility, testosterone replacement suppresses LH and FSH through the negative feedback mechanism, reducing Leydig cell stimulation and spermatogenesis. This leads to a reduction in testicular size (atrophy) and a significant reduction in sperm production in most men on TRT.
- Testicular atrophy is cosmetically noticeable in some men and is a source of concern for others — though it does not affect the hormonal benefits of TRT
- Fertility suppression is the more clinically significant consequence for younger men who may wish to conceive — see our dedicated TRT and fertility article for management options
- hCG co-administration alongside TRT maintains testicular stimulation, preserving testicular size and spermatogenesis in most men
4: Acne and Skin Changes
Testosterone stimulates sebaceous (oil) gland activity in the skin, which can cause or worsen acne — particularly in men with a genetic predisposition to acne or those who experienced significant acne during adolescence.
- Typically mild to moderate; rarely severe in TRT doses (compared to supraphysiological doses used illicitly)
- Most common on back, shoulders, and chest — classic androgen-sensitive areas
- Management: topical treatments (benzoyl peroxide, salicylic acid, topical antibiotics), improved skincare hygiene, dose adjustment if severe, dermatological referral if needed
- Often improves after the initial months as the body adjusts to the new hormonal environment
5: Hair Loss (Male Pattern Baldness Acceleration)
TRT can accelerate male pattern hair loss (androgenetic alopecia) in men who are genetically predisposed to it. The mechanism involves dihydrotestosterone (DHT) — the potent androgen produced by 5-alpha reductase conversion of testosterone — acting on genetically sensitive hair follicles and causing progressive miniaturisation.
- TRT does not cause hair loss in men without genetic susceptibility — it is not a universal TRT side effect
- In men with a family history of male pattern baldness, TRT may accelerate a process that would have occurred anyway
- Management options: topical minoxidil (Rogaine), oral minoxidil at low doses, finasteride (5-alpha reductase inhibitor — note: finasteride reduces DHT conversion and may affect TRT efficacy for some symptoms; requires clinical discussion), scalp care
- Men who are already significantly bald are not at meaningful additional risk beyond what genetics has already determined
6: Prostate Health Considerations
PSA (prostate-specific antigen) monitoring is a standard component of TRT monitoring — not because TRT causes prostate cancer, but because testosterone can stimulate growth of existing prostate tissue, and because an undetected prostate cancer present before TRT is initiated could be accelerated by testosterone exposure.
What the Evidence Actually Shows
The long-standing concern that TRT causes prostate cancer has been substantially revised in the medical literature. Multiple large studies and meta-analyses have not demonstrated an increased incidence of prostate cancer in men on TRT compared to untreated controls. Current evidence supports the concept of a ‘saturation model’ — prostate androgen receptors saturate at relatively low testosterone levels, and further increases beyond that threshold do not meaningfully increase prostate cancer risk.
- PSA should be measured at baseline before starting TRT and at 3 and 12 months, then annually
- TRT is contraindicated in men with known or suspected prostate cancer — a baseline PSA and prostate assessment are essential before initiation
- A significant rise in PSA (>1.4 ng/mL increase in any 12-month period, or PSA above 4.0 ng/mL) warrants urological referral
- Benign prostatic hyperplasia (BPH) symptoms — urinary flow issues, frequency — should be monitored; TRT may worsen these in some men
7: Sleep Apnoea
TRT can worsen pre-existing obstructive sleep apnoea (OSA) or, less commonly, precipitate it in men with predisposing anatomy. Testosterone increases upper airway collapsibility in some men and stimulates red blood cell production, both of which can contribute to sleep-disordered breathing.
- Men with known or suspected sleep apnoea should be assessed and ideally treated before starting TRT
- New or worsening snoring, witnessed apnoeas, or excessive daytime sleepiness during TRT should prompt sleep apnoea assessment
- Not a common or severe issue in most TRT patients, but worth monitoring in men with risk factors (obesity, large neck circumference, craniofacial anatomy)
8: Mood and Psychological Effects
Testosterone has significant effects on mood, drive, and emotional regulation — which is why restoring it in deficient men typically produces substantial improvements in all these domains. However, in some men, particularly those on supraphysiological doses or those with elevated oestradiol, mood disturbance can occur.
- Irritability or mood swings — often related to dose timing with injectable preparations (peaks and troughs) rather than TRT itself; more frequent dosing or switching to a gel can smooth the hormonal curve
- Emotional sensitivity in the early weeks — as hormonal balance shifts from the deficient baseline, some temporary adjustment is common
- Mania or aggressive behaviour — not expected at physiological TRT doses; associated with supraphysiological use; appropriate dosing prevents this
Complete Side Effect Reference: At a Glance
One aspect of TRT risk that is rarely discussed is the risk of under-treatment — of maintaining testosterone levels that are still too low to produce the full clinical benefit, either through excessive caution about side effects or inadequate dose optimisation.
Men who are under-treated on TRT — who have testosterone levels that are improved but still below their optimal physiological range — continue to carry the health risks of testosterone deficiency: bone loss, cardiovascular risk, metabolic dysfunction, and sustained psychological impact. Managing TRT well means finding the appropriate therapeutic level, not simply the lowest dose that avoids side effects.
This is why at Vitalis Luxe Clinic we take a precision approach to TRT monitoring — not just screening for side effects, but actively ensuring that testosterone, free testosterone, oestradiol, and haematocrit are all within their optimal therapeutic ranges.
Frequently Asked Questions
What are the most common TRT side effects?
The most common side effects of properly dosed TRT are erythrocytosis (elevated red blood cell count, which raises haematocrit), testicular atrophy due to LH/FSH suppression, and in men with higher body fat, elevated oestradiol which can cause water retention, mood changes, or gynaecomastia. Acne is also common in the early months. All of these are detectable through routine monitoring and manageable through dose adjustment or adjunct treatment
Is TRT dangerous?
Properly prescribed and monitored TRT is not dangerous in the vast majority of men. The risks of TRT — principally erythrocytosis, oestradiol elevation, and prostate stimulation — are detectable through routine blood tests and entirely manageable. The more clinically relevant comparison is between the managed risks of treated TRT versus the documented, progressive health consequences of untreated testosterone deficiency — which include bone loss, cardiovascular deterioration, metabolic dysfunction, and sustained psychological harm.
Does TRT cause prostate cancer?
Current clinical evidence does not support the claim that TRT causes prostate cancer. Multiple large studies have not demonstrated an increased incidence of prostate cancer in men on TRT. A PSA test before starting TRT is essential to exclude pre-existing prostate pathology, and PSA is monitored regularly throughout treatment. TRT is contraindicated in men with known or suspected prostate cancer.
Will TRT make me aggressive or change my personality?
Properly dosed TRT — which aims to restore testosterone to within the normal physiological range, not to supraphysiological levels — does not cause aggression. Aggressive behaviour is associated with supraphysiological testosterone use (as in illicit anabolic steroid use), not with clinically managed TRT. Many men on TRT report improved mood, reduced irritability, and greater emotional stability compared to their deficient baseline.
Does TRT cause hair loss?
TRT can accelerate male pattern hair loss in men who are genetically predisposed to it — but it does not cause hair loss in men without this genetic susceptibility. If your father or maternal grandfather retained most of their hair, TRT is unlikely to cause significant hair loss. If baldness runs strongly in your family, TRT may advance a process that would have occurred regardless, and hair loss prevention treatments (minoxidil, finasteride) can be discussed as part of your overall management.
What happens to my haematocrit on TRT and why does it matter?
Testosterone stimulates red blood cell production, which can raise haematocrit (the proportion of blood occupied by red cells). If haematocrit rises above 54%, blood viscosity increases and the risk of clotting events rises. This is the most clinically important TRT side effect to monitor. It is managed through dose adjustment, switching to a flatter-profile preparation, or therapeutic venesection (blood donation). At Vitalis Luxe Clinic, haematocrit is measured in every monitoring blood test.
Can TRT cause heart problems?
Well-managed TRT in men with confirmed deficiency is not associated with increased cardiovascular risk based on current evidence. In fact, some evidence suggests TRT may be cardioprotective through improvements in body composition, insulin sensitivity, and lipid profiles. The erythrocytosis risk described above requires monitoring because elevated haematocrit increases viscosity, but this is detected and managed before it becomes a clinical problem.
How often should I have blood tests on TRT?
At Vitalis Luxe Clinic, our standard monitoring protocol includes a blood test at 6–8 weeks after starting TRT, a full review at 3–6 months, and annual monitoring panels thereafter. More frequent testing may be indicated during the dose optimisation phase or if side effects are noted. Regular monitoring is not optional — it is the foundation of responsible TRT practice and what distinguishes clinically managed TRT from unmonitored self-administration.